Dauch reinstated with a Neutral at JPMorgan
JPMorgan reinstated coverage of Dauch with a Neutral rating and $8 price target following a period of restriction in conjunction with the company's acquisition of UK-based Dowlais. While the firm sees a more favorable setup for patient investors starting late 2027 as one-time free cash flow drags taper and synergies in